Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOVX GeoVax Labs	$0.93 -2.1%	$1.00	$0.73 ▼ $11.18	$14.13M	3.45	689,229 shs	253,812 shs
INDP Indaptus Therapeutics	$11.19 +2,336.3%	$0.40	$1.77 ▼ $67.48	$179.30M	1.31	61,789 shs	33,388 shs
NOVN Novan		$0.00	$0.08 ▼ $3.33	$2.64M	-0.06	602,421 shs	7.19 million shs
PIRS Pieris Pharmaceuticals	$13.60	$15.17	$6.20 ▼ $18.68	$17.95M	0.61	83,101 shs	51,728 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOVX GeoVax Labs	+5.93%	+2.74%	-12.04%	-14.41%	-52.85%
INDP Indaptus Therapeutics	+24.76%	+39.54%	+41.57%	-22.19%	-80.63%
NOVN Novan	0.00%	0.00%	0.00%	0.00%	0.00%
PIRS Pieris Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+55.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GOVX GeoVax Labs	3.4754 of 5 stars	3.6	5.0	0.0	0.0	2.8	1.7	0.6
INDP Indaptus Therapeutics	2.5004 of 5 stars	3.5	2.0	0.0	0.0	2.7	1.7	0.6
NOVN Novan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PIRS Pieris Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GOVX GeoVax Labs	3.29	Buy	$11.10	1,093.29% Upside
INDP Indaptus Therapeutics	3.00	Buy	$8.50	-24.01% Downside
NOVN Novan	0.00	N/A	N/A	N/A
PIRS Pieris Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NOVN, PIRS, INDP, and GOVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/2/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $9.00
4/16/2025	GOVX GeoVax Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/15/2025	GOVX GeoVax Labs	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.50
4/10/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/28/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GOVX GeoVax Labs	$3.95M	3.58	N/A	N/A	$0.48 per share	1.94
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$0.39 per share	N/A
NOVN Novan	$24.71M	0.00	N/A	N/A	$0.19 per share	0.00
PIRS Pieris Pharmaceuticals	$42.81M	0.42	N/A	N/A	$21.66 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GOVX GeoVax Labs	-$24.99M	-$3.65	N/A	N/A	N/A	-438.20%	-511.96%	-286.58%	8/5/2025 (Estimated)
INDP Indaptus Therapeutics	-$15.02M	-$1.49	N/A	N/A	N/A	N/A	-333.02%	-216.36%	8/11/2025 (Estimated)
NOVN Novan	-$31.31M	-$1.32	N/A	N/A	N/A	-128.61%	-700.28%	-39.58%	N/A
PIRS Pieris Pharmaceuticals	-$24.54M	-$12.10	N/A	∞	N/A	-39.71%	-80.93%	-59.55%	N/A

Latest NOVN, PIRS, INDP, and GOVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	INDP Indaptus Therapeutics	-$0.41	-$0.32	+$0.09	-$0.32	N/A	N/A
5/1/2025	Q1 2025	GOVX GeoVax Labs	-$0.59	-$0.45	+$0.14	-$0.45	$0.75 million	$1.64 million
3/27/2025	Q4 2024	GOVX GeoVax Labs	-$0.79	-$0.30	+$0.49	-$0.30	$2.38 million	$3.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
NOVN Novan	N/A	N/A	N/A	N/A	N/A
PIRS Pieris Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GOVX GeoVax Labs	N/A	3.62	3.62
INDP Indaptus Therapeutics	N/A	1.90	1.90
NOVN Novan	N/A	0.74	0.72
PIRS Pieris Pharmaceuticals	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GOVX GeoVax Labs	6.09%
INDP Indaptus Therapeutics	7.06%
NOVN Novan	14.51%
PIRS Pieris Pharmaceuticals	40.11%

Insider Ownership

Company	Insider Ownership
GOVX GeoVax Labs	1.20%
INDP Indaptus Therapeutics	20.60%
NOVN Novan	1.30%
PIRS Pieris Pharmaceuticals	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GOVX GeoVax Labs	10	15.19 million	15.01 million	Not Optionable
INDP Indaptus Therapeutics	6	16.03 million	12.73 million	Not Optionable
NOVN Novan	90	28.02 million	27.65 million	Not Optionable
PIRS Pieris Pharmaceuticals	140	1.32 million	1.24 million	Optionable

NOVN, PIRS, INDP, and GOVX Headlines

Recent News About These Companies

Pieris Pharmaceuticals Inc

April 18, 2025 | money.usnews.com

Palvella Therapeutics Inc (PVLA)

December 27, 2024 | investing.com

Main Line biotech firm completes reverse merger, raises $78.9 million

December 17, 2024 | bizjournals.com

One new option listing and one option delisting on December 16th

December 17, 2024 | markets.businessinsider.com

Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments

December 14, 2024 | msn.com

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

December 14, 2024 | markets.businessinsider.com

(PIRS) Trading Report

November 27, 2024 | news.stocktradersdaily.comN

PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS

November 20, 2024 | businesswire.com

How To Trade (PIRS)

November 17, 2024 | news.stocktradersdaily.comN

Pieris Pharmaceuticals announces first patient dosed in SELVA Phase 3 trial

November 7, 2024 | markets.businessinsider.com

(PIRS) Investment Analysis and Advice

November 6, 2024 | news.stocktradersdaily.comN

Pieris loses Servier as partner for cancer immunotherapies

October 29, 2024 | pharmaphorum.comP

(PIRS) Technical Data

October 26, 2024 | news.stocktradersdaily.comN

Aridis Pharmaceuticals (OTC:ARDS) Stock Quotes, Forecast and News Summary

October 19, 2024 | benzinga.com

Learn to Evaluate (PIRS) using the Charts

October 16, 2024 | news.stocktradersdaily.comN

Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

October 15, 2024 | globenewswire.com

(PIRS) Trading Signals

October 7, 2024 | news.stocktradersdaily.comN

Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations

October 3, 2024 | globenewswire.com

Kubota Pharmaceutical Holdings Co., Ltd. (4596.T) Stock Price, News, Quote & History - Yahoo Finance

September 24, 2024 | finance.yahoo.com

Pieris Pharmaceuticals Inc.

September 24, 2024 | barrons.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NOVN, PIRS, INDP, and GOVX Company Descriptions

GeoVax Labs NASDAQ:GOVX

$0.93 -0.02 (-2.08%)

As of 11:45 AM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Indaptus Therapeutics NASDAQ:INDP

$11.18 +10.73 (+2,336.29%)

As of 12:02 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Novan NASDAQ:NOVN

Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.

Pieris Pharmaceuticals NASDAQ:PIRS

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time